Diagnostic Biomarkers in Metastatic Breast Cancer Lei Huo MD PhD The University of Texas MD Anderson Cancer Center.

Slides:

Advertisements

Similar presentations

UNDERWRITING CORRELATION FOR CANCER CASES. Are we going to accept a proposed insured with known cancer?

Advertisements

Eyas M. Hattab, M.D. Department of Pathology and Laboratory Medicine Scientific Committee of the ADIAP 25th Annual Congress and the 5th JSP International.

National Institute of Oncology Rabat-Morocco. National Institute of Oncology I.N.O. Rabat, Morocco : New Cases.

An 80-year-old female presented with an ulcerated nodule on the left cheek. An excision was performed.

Delving into the Occult. Introduction Occult From the Latin word occultus meaning clandestine, hidden or secret Occult Cancer Carcinoma of unknown primary.

Pancreas Cancer Nimisha K. Parekh, MD, MPH

What is TNM? TNM is a system for classifying malignant tumours ! It is a cancer staging system, which describes the extent of a person's cancer ! Most.

Eva Compe´rat1, Fan Zhang1, Cedric Perrotin2, Thierry Molina1, Pierre Magdeleinat2,Beatrice Marmey1, Jean-Francois Re´gnard2, Josee Audouin1 and Saphie.

Inhibin, dimetric 32-kDa peptide hormone that belongs to the transforming growth factor beta family, it is produced by ovarian granulosa cells and testicular.

Cancer Dr. Raid Jastania. Cancer In the US: 1.3 million new cancer cases in 2002 >500,000 death of cancer Increase cancer death in men due to lung cancer.

* For those free of cancer at beginning of age interval. Source: DevCan: Probability of Developing or Dying of Cancer Software, Version Statistical.

Anxiety Arthritis Asthma Atrial Fibrillation Bone Marrow Transplantation BPH Breast Cancer Colon Cancer Coronary Artery Disease Depression Diabetes End.

* For those free of cancer at beginning of age interval. Source: DevCan: Probability of Developing or Dying of Cancer Software, Version Statistical.

SYB Case 2 By: Amy. History 63 y/o female History of left breast infiltrating duct carcinoma s/p mastectomy in 1996 and chemotherapy ER negative, PR negative,

Cancer By: Erionne. What is Cancer Cancer begins in your cells, which are the building blocks of your body. Normally, your body forms new cells as you.

Imaging Questions in Ovarian Cancer Susanna I. Lee, MD, PhD.

Session 4. Biopsies. Professor Sarah Pinder. Case A - SP

Human Biology Sylvia S. Mader Michael Windelspecht

Bone Marrow Biopsy Focal involvement by small B-cell neoplasm without significant plasmacytic differentiation (CD3-, CD20+, PAX5+, kappa IHC-, lambda IHC-,

RT-PCR:PRKWNK1, WNK1, T39 T40 (232 bp) Bedingungen: 2% TBE 90 V 1h 40 min 9 µl PCR-Probe 2 µl Ladepuffer _Gewebe_1_A1_T39T40_calb M

Changes in Breast Cancer Reports After Second Opinion Dr. Vicente Marco Department of Pathology Hospital Quiron Barcelona. Spain.

وما أوتيتم من العلم إلا قليلاً. Prepared by: Abdo A Elfiky.

RT-PCR: PRKWNK1,WNK1, T39 T40 (232 bp), Reamplifikation _Reampli_Gewebe_1_A1_T39T40_calb Bedingungen: 2% TBE 90V 1h 40min 9 µ Reampli-Probe 2 µl.

HEAD/NECK OF THE SKIN ANALYTIC vs. NON-ANALYTIC by YEAR N = 1800.

Diagnostic Challenge Pathology for Neurosurgery & Neurology Residents Department of Pathology University of Oklahoma Health Sciences Center, Oklahoma City,

RT-PCR: PC326, T146 T147 (240 bp) _Gewebe_1_B1_T146T147_calb Bedingungen: 2% TBE 90V 1h 40min 9 µl PCR-Probe 2 µl LB M

By: Ashley Rodriguez, Yara parada, Briana Mendoza, Jackie Hernandez

RCS 6080 Medical and Psychosocial Aspects of Rehabilitation Counseling Cancer.

Esophagus cancer Dr Sanei Associated professor of pathology GI and Liver patholoogist.

Diagnostic Challenge Pathology for Neurosurgery & Neurology Residents Department of Pathology University of Oklahoma Health Sciences Center, Oklahoma City,

INTESTINAL DIFFERENTIATION IN PULMONARY ADENOCARCINOMA Paul Theunissen, MD, PhD, Nick van Rodijnen, Dept. of pathology, Atrium Medisch Centrum, Heerlen,

Understanding Cancer and Related Topics

ABSENCE OF TTF-1 EXPRESSION IN INVASIVE DUCTAL CARCINOMAS-NOS OF BREAST M. Bisceglia, M. Vairo, L. Zaffarano, G. Perrone, M. Cassano, A. Danza. Department.

RT-PCR: BCLG, T84 T85 (487bp) _Gewebe_1_A2_T84T85_calb Bedingungen: 2% TBE 90V 1h 45min 9 µl PCR-Produkt 2 µl LB M

Ovary and Primary Peritoneal Carcinoma Anatomic sites of the ovary and peritoneum. Compton, C.C., Byrd, D.R., et al., Editors. AJCC CancerStaging Atlas,

Neoplasia p.2 65 Ovarian papillary cystadenoma 285 Adenoma (large intestine) 68 Adenocarcinoma (large intestine) 69 Small cell lung carcinoma (= SCLC)

Diagnostic Challenge Pathology for Neurosurgery & Neurology Residents Department of Pathology University of Oklahoma Health Sciences Center, Oklahoma City,

Warm-up Cancer Look at the chart from the National Cancer Institute with the numbers of new cases of different types of cancer and the estimated number.

부산대학교병원 김 주 연 2012 년 세포병리학회 가을학술대회 월례집담회.  F/52  Past history : 03’ left breast operation, on follow up  Lower abdominal pain (12’ April)  Physical.

Cancer: causes abnormal and uncontrolled cell growth to occur within body Because cancer cells continue to grow and divide, they are different from normal.

Kyung Hee University, Seoul, Korea GI Conference UGI Conference Presented by Byeong-Joo Noh Supervised by Youn-Wha Kim Kyung Hee University, Seoul, Korea.

Neoplasia Basics, Grading and Staging Kimiko Suzue MD, Ph.D. Department of Pathology Mt. Sinai Hospital.

Annals of Oncology 23: 298–304, 2012 종양혈액내과 R4 김태영 / prof. 김시영.

1. Multiple Primary and Histology Rules 101 Format of MP/H Materials.

Supraclavicular metastasis from urothelial bladder carcinoma: A case report S. Farmahan, T. Mirza, P. Ameerally Oral Maxillofacial Department, Northampton.

간담도 암에서의 PET 의 활용 핵의학과 홍일기. 18 F-FDG PET: Warburg effect.

NPCR Data Completeness and Quality Audits Review of: Collaborative Stage and Surgery Data Mary Lewis, CTR NPCR Program Consultant.

GS Case M/53 S Small intestine, segmentectomy.

Figure 5. Histological specimen of sentinel lymph node after second excision. (A) Histological examination of in situ follicular lymphoma in sentinel lymph.

Volume 131, Issue 4, Pages (April 2007)

Down-Regulation of Annexin A10 in Hepatocellular Carcinoma Is Associated with Vascular Invasion, Early Recurrence, and Poor Prognosis in Synergy with.

Cancer Unknown Primary

Development of preclinical models for the guidance of precision medicine. Development of preclinical models for the guidance of precision medicine. A,

KRAS, NRAS, PIK3CA Exon 20, and BRAF Genotypes in Synchronous and Metachronous Primary Colorectal Cancers Katharina Balschun, Jochen Haag, Ann-Kathrin.

Figure 2 Examples of histopathological validation

Prognostic Significance of TAZ Expression in Resected Non-Small Cell Lung Cancer Mian Xie, MD, PhD, Li Zhang, MD, Chao-Sheng He, MD, Jin-Hui Hou, MD,

Adrenal Metastases in Lung Cancer: Clinical Implications of a Mathematical Model Lyudmila Bazhenova, MD, Paul Newton, PhD, Jeremy Mason, PhD, Kelly Bethel,

Identification of MGB1 as a Marker in the Differential Diagnosis of Lung Tumors in Patients with a History of Breast Cancer by Analysis of Publicly Available.

The Mucinous Lung Tumor Signature is highly enriched in colorectal, stomach, pancreatic, lung (adenocarcinoma; LUAD), and breast cancers The Mucinous Lung.

IMITAB® (Imatinib Mesylate BP Tablets)

Empiric versus Site-Directed Chemotherapy in Cancer of Unknown Primary

ROYAL COLLEGE OF PHYSICIANS,

・FFPE tumor tissue array (Biochain, cat. T )

Overview of cancer genetics in the SMP1 cohort: lung cancer (A), breast cancer (B), colorectal adenocarcinoma (except mucinous subtype) (C), prostate cancer.

PD-L1 expression by melanocytes is observed in geographic association with TILs but does not depend on BRAF V600E. PD-L1 expression by melanocytes is observed.

IL6 mRNA is not detected in metastatic prostate cancer cells.

GATA-3 immunostaining was scored semiquantitatively; tumors with

MGA271 mediates in vitro ADCC across a panel of ATCC cancer cell lines exhibiting a range of B7-H3 expression. MGA271 mediates in vitro ADCC across a panel.

Correlations between comutations of HRR-BER or HRR-MMR and tumor mutational burden, neoantigen load, and MSI-H. Correlations between comutations of HRR-BER.

Presentation transcript:

Diagnostic Biomarkers in Metastatic Breast Cancer Lei Huo MD PhD The University of Texas MD Anderson Cancer Center

Metastatic breast cancer Unknown primary Metastatic tumors to breast: –Melanoma –Carcinoma: ovary, lung, GI, kidney, skin (squamous) – (Lymphoma)

Breast carcinoma GCDFP-15 mammaglogin GATA-3 Ovarian carcinoma WT1 PAX8 Lung adenocarcinoma TTF-1 Naspin A Pancreas (DPC4/SMAD4) Stomach Cholangiocarcinoma ER/PR+ER/PR– +/– CK7/CK20 –/– Melanoma cocktail S100 melanA HMB-45 MiTF SOX10 Renal cell carcinoma PAX8 PAX2 Hepatocellular Carcinoma HepPar 1 Urothelial carcinoma GATA-3, uroplakin III +/+–/+ Pancreas (DPC4/SMAD4) Stomach Cholangiocarcinoma Breast carcinoma ER/PR, GCPFP-15, mammaglobin, GATA-3 Colon CDX2 Stomach (CDX2) Ovarian mucinous carcinoma (ER, PAX8)

Sensitivity in breast cancer: GCDFP-15: 60% Mammaglobin: 80% GATA-3: 70-80%

Marker Any positive staining >5% positive staining GCDFP-15 9 (14%) 4 (6%) MAM 16 (25%) 7 (11%) GCDFP-15/ MAM 19 (30%) 9 (14%) Marker Any positive staining >5% positive staining GCDFP-15 (n=110) 23 (21%)13 (12%) MAM (n=64)25 (41%)6 (9%) GCDFP-15/ MAM (n=56) 24 (43%) 6 (11%) Primary TN (n=63)Metastatic TN (n=118) Huo L et al. Histopathology 2013

62 primary TNBC (all resection specimens) 68 metastatic TNBC (44 biopsies, 24 excision specimens) Regional lymph nodes 19 Lung25 Liver 9 Bone4 Soft tissue3 Ovary2 GI tract2 Distant LN1 Bladder1 Trachea1 Uterus1 Huo L et al. Histopathology 2015

Positive: >5% Focal: 5% or less Negative: no staining GCDFP-15: clone D6, Covance Mammaglobin: clone 1A5, Biocare Medical GATA-3: clone HG3-31, Santa Cruz Biotechnology Antibodies Positivity

MarkerMammaglobin GATA-3GCDFP-15PositiveFocalNegative Positive (n=14) Positive102 Focal100 Negative028 Focal (n=11) Positive000 Focal100 Negative028 Negative (n=37) Positive100 Focal201 Negative1527 Total (n=62) 7946 Primary TN Huo L et al. Histopathology 2015

Primary TN (n=62) Marker Any positive staining >5% positive staining GATA-325 (40%)14 (23%) GCDFP-15 9 (15%)4 (6%) MAM16 (26%) 7 (11%) GATA-3/ GCDFP-1529 (47%)15 (24%) GATA-3/ MAM34 (55%)19 (31%) GCDFP-15/ MAM19 (31%) 9 (15%) Any marker35 (56%)19 (31%) All markers3 (5%) 1 (2%)

GATA-3

Metastatic TN (n=68) Marker Any positive staining >5% positive staining GATA-330 (44%)18 (26%) GCDFP-1511 (16%)6 (9%) MAM22 (32%)10 (15%) GATA-3/ GCDFP-1532 (47%)23 (34%) GATA-3/ MAM41 (60%)27 (40%) GCDFP-15/ MAM26 (38%)14 (21%) Any marker42 (62%)30 (44%) All markers 6 (9%)0 (0%)

GATA-3mammaglobinGCDFP-15

GATA-3 is a more sensitive marker than GCDFP-15 and mammaglobin in TNBC A panel of stains including all three markers may increase the diagnostic accuracy for tissue origin The sensitivity in TNBC is moderate even when all three markers are combined, therefore negative staining for all markers does not exclude breast origin

Acknowledgements Michael Deavers Michael Gilcrease Yun Gong Ming Guo Kelly Hunt Erika Resetkova Yun Wu Amy Zhang Jinxia Zhang Hui Chen Herminia Patino Ariana Trevino Kim-Anh Vu